Market Trends of Cardiovascular Drugs Industry
Hypertension Segment is Expected to Witness Significant Growth Over the Forecast Period
The hypertension segment is growing and is anticipated to hold a significant share during the forecast period. When blood pressure is excessively high, it is called hypertension. If one has high blood pressure for a long period but doesn't regulate it, hypertensive heart disease may develop. Heart failure or other health issues could result from increased stress on patients' hearts. Thus, cardiovascular drugs are used to control high blood pressure (high BP) or hypertension. Hence, with the increasing burden of hypertension among the target population, the segment is expected to grow.
Hypertension significantly increases the risk of heart, brain, and kidney diseases. Thus, the rising burden of hypertension among the target population increases the demand for drugs used to treat hypertension. For example, the data updated by the World Health Organization (WHO) in March 2023 mentioned that the number of people living with hypertension doubled to 1.28 billion in 2021 from previous years, which increased drastically over the past few decades. Hence, WHO has set a global record to reduce the prevalence of hypertension by 30% by 2030. Additionally, as per the data released by the American College of Cardiology in December 2022, nearly 2,770 DALYs per 100,000 persons related to CVDs were caused by high blood pressure and is expected to drive the demand for the development and the availability of cardiology drugs, fueling the segment's growth.
Furthermore, frequent product approval and innovation are expected to drive the segment's growth. For instance, in May 2022, Zydus Lifesciences Limited's subsidiary, Zydus Worldwide DMCC, received tentative approval from the FDA to market Selexipag tablets used to treat pulmonary arterial hypertension (PAH) in adults. In addition, in February 2022, the FDA approved Norliqva (amlodipine) oral solution for the treatment of hypertension in adults and children 6 years and older to lower blood pressure and coronary artery disease. Such approvals are anticipated to accelerate the growth of the segment. Hence, owing to factors such as the rising burden of hypertension and product approvals, the studied segment is expected to grow during the forecast period.
North America is Expected to Hold a Significant Share of the Market During the Forecast Period
North America holds a significant share of the cardiovascular drugs market and is expected to continue its growth trend throughout the forecast period. The major factors contributing to the growth of the region are a sedentary lifestyle, lack of physical activity, lack of proper diet, anxiety, and stress, resulting in diabetes and obesity. These conditions further lead to a rise in the prevalence of multiple cardiovascular conditions like coronary artery disease, strokes, and atrial fibrillation, among other conditions.
Among other countries of the region, the United States contributes significantly to the studied market growth owing to a high prevalence and incidence of CVDs. The data updated by Cedars-Sinai in January 2022 shows that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass or bypass surgery, is the most common type of heart surgery and more than 300,000 people have successful bypass surgery in the United States each year. This shows a rising burden of cardiovascular diseases in the country and demands the development of drugs for treatment in the United States.
In addition, the data updated in July 2022 by the Centers for Disease Control and Prevention (CDC) shows that coronary heart disease is the most common type of heart disease, and approximately 20.1 million adults aged 20 and older had the disease in the United States in the previous year. Additionally, as per the CDC data, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States have a heart attack every year. Thus, the high burden of cardiovascular diseases demands the availability of advanced drugs for treatment and is expected to drive the overall market's growth in the region.
Moreover, product launches, approvals, and clinical trials are increasing in the region, which is anticipated to drive the growth of the market studied over the forecast period. For instance, in December 2021, the FDA approved Leqvio (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year after an initial dose and one at three months. Developed by Novartis, Leqvio provides effective LDL-C reduction of up to 52% against a placebo for certain people with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statin therapy. In addition, in August 2021, Health Canada approved MYINFLA 0.5 mg for the reduction of cardiovascular risk in patients with coronary disease. Therefore, the market is expected to witness a high growth rate over the forecast period due to the factors mentioned above in North America.
